- Home
- IFRX
IFRX
InflaRx N.V.
as 07-26-2024 4:00pm EST
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
| Founded: | 2007 | Country: | Germany |
| Employees: | N/A | City: | N/A |
| Market Cap: | 96.6M | IPO Year: | 2017 |
| Target Price: | $13.50 | AVG Volume (30 days): | 71.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.78 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.14 - $4.30 | Next Earning Date: | 08-08-2024 |
| Revenue: | $107,746 | Revenue Growth: | N/A |
| Revenue Growth (this year): | 558.02% | Revenue Growth (next year): | 275.54% |
Latest InflaRx N.V. News
IFRX Breaking Stock News: Dive into IFRX Ticker-Specific Updates for Smart Investing
MT Newswires
a month ago
Sector Update: Health Care Stocks Rise in Late Afternoon Trading
MT Newswires
a month ago
Sector Update: Health Care Stocks Advance Monday Afternoon
MT Newswires
a month ago
Sector Update: Health Care
MT Newswires
a month ago
InflaRx Anti-Inflammatory Drug Chosen for Phase 2 Acute Respiratory Distress Syndrome Trial; Shares Rise
GlobeNewswire
a month ago
InflaRx’s GOHIBIC (Vilobelimab) Selected for First BARDA-Sponsored Clinical Trial to Evaluate Novel Host-Directed Therapeutics for Acute Respiratory Distress Syndrome (ARDS)
GlobeNewswire
2 months ago
InflaRx Hosts R&D Event Highlighting the Promise of INF904
GlobeNewswire
2 months ago
InflaRx Presents New Analysis of PANAMO Phase III Trial in Severe COVID-19 at ATS 2024 Showing Potential Synergy With Vilobelimab When Used in Combination with Other Immunomodulators
GlobeNewswire
3 months ago
InflaRx Reports First Quarter 2024 Financial Results and Provides Business Update
Compare IFRX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IFRX InflaRx N.V. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.